Comparative Pharmacology
Head-to-head clinical analysis: DOXY SLEEP AID versus DOXYLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY SLEEP AID versus DOXYLAMINE.
DOXY-SLEEP-AID vs Doxylamine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxy-Sleep-Aid is a sedative-hypnotic drug that acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. It selectively binds to α1 subunits of GABA-A receptors, promoting sleep onset and maintenance.
Doxylamine is a first-generation antihistamine with sedative properties. It acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also possesses anticholinergic activity.
Doxylamine succinate 25 mg orally once daily at bedtime.
12.5–25 mg orally at bedtime for insomnia; 25 mg orally every 4–6 hours as needed for allergies (max 150 mg/day).
None Documented
None Documented
Clinical Note
moderateDoxylamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine."
Clinical Note
moderateDoxylamine + Nefazodone
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone."
Clinical Note
moderateDoxylamine + Tranylcypromine
"Doxylamine may increase the anticholinergic activities of Tranylcypromine."
Clinical Note
moderateDoxylamine + Sertraline
10-12 hours; extended in elderly and hepatic impairment
10-12 hours; prolonged in elderly and hepatic impairment.
Renal: 40% unchanged; biliary/fecal: 60% as metabolites
Renal (approximately 60% as unchanged drug and metabolites, primarily as N-desmethyldoxylamine and other metabolites); biliary/fecal (minor).
Category C
Category A/B
Antihistamine (Sedating)
Antihistamine (Sedating)
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline."